WHWK

SEC Filing Summary: Zeta Acquisition Corp. II (10-Q)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2009, for Zeta Acquisition Corp. II (Note: The input metadata referenced "Whitehawk Therapeutics," but the filing text explicitly identifies the registrant as Zeta Acquisition Corp. II). The company is a Delaware corporation organized as a "blank check" shell company in the development stage. Its sole objective is to investigate and acquire a target business to achieve long-term growth. The company has no specific business plan, no active operations, and has generated no revenue since its inception on November 16, 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Position: Cash and cash equivalents increased from $7,508 at December 31, 2008, to $16,775 at June 30, 2009, primarily due to $25,000 in proceeds from notes payable issued to stockholders.
• Liabilities: Total liabilities increased from $6,108 to $26,907. This increase is driven by the new $25,000 in notes payable to stockholders, partially offset by a reduction in accounts payable and accrued expenses.
• Operating Loss: The net loss for the six months ended June 30, 2009, was $7,032, compared to a net loss of $20,327 for the same period in 2008. The reduction in loss is attributed to lower professional service fees in the current period compared to the formation and registration costs incurred in 2008.
• Equity Deficit: The company moved from a positive stockholders' equity of $1,400 at year-end 2008 to a deficit of $(5,632) by June 30, 2009, due to accumulated operating losses exceeding the initial capital raised.

Outlook, Risks, and Management Commentary

• Going Concern: Management explicitly states that the company has generated no revenues and is dependent on capital investment or financing to fund operations. The financial statements are presented on a going concern basis, but there is no assurance the company can satisfy cash requirements for the next twelve months.
• Business Plan: The company intends to identify a target business for acquisition or merger. It does not restrict potential targets to any specific industry or geography. No target has been identified to date.
• Financing Needs: Future operations depend on funds in the treasury, deferral of fees, or additional loans/investments from stockholders and management. The company currently has no revenue-generating activities.
• Risks: Risks include the inability to find a suitable acquisition target, the financial instability of potential targets, and the general risks associated with early-stage development companies. The company is classified as a "shell company" and a "blank check" company.
• Unusual Items: The company utilizes office space and equipment of an officer/director at no cost. Notes payable to stockholders bear 6% interest and are due on demand.

Key Facts for Investor Verification

• Company Identity: Verify that the filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc., as the text explicitly names Zeta.
• Capital Dependency: Confirm the company's reliance on related-party financing (notes payable) to remain solvent, as it has no operating cash flow.
• Shell Status: Acknowledge the company is a shell with nominal assets and no operations, posing high risk for investors seeking operational returns.
• Debt Obligations: Note the $25,000 in notes payable to stockholders are due on demand, creating immediate liquidity pressure if called.
• Accumulated Deficit: Verify the cumulative net loss of $55,632 since inception, which has eroded the initial equity capital.